Pcsk 9 mAb denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for pcsk9 mab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Requires Prior Authorization for PCSK9 Monoclonal Antibodies

UnitedHealthcare requires prior authorization for PCSK9 inhibitor monoclonal antibodies because they are high-cost specialty agents. The prior-authorization process is UHC's mechanism for confirming that the clinical criteria in its published coverage policy are satisfied before the claim is paid. A denial at this stage most often means the authorization was either not submitted before dispensing, was submitted with incomplete documentation, or was reviewed and found not to meet the policy criteria. Each scenario has a distinct path forward.

## Why This Denial Is Appealable

If the prior authorization was denied on clinical grounds, you have the full internal and external appeal rights described under ACA §2719 and ERISA §503. If the denial is administrative (authorization not obtained in time), some plans allow a retroactive appeal based on medical emergency or prescriber error — review your plan's retroactive-authorization provision. The standard external-review window is approximately 4 months from denial, and an expedited review is available when your health is at immediate risk.

## The Appeal Process and Timeline

1. Determine the denial basis: clinical (criteria not met) versus administrative (no auth on file) — the path differs. 2. For clinical denials: file a Level 1 internal appeal within the deadline stated on the denial letter, with a complete clinical package (see below). 3. For administrative denials: ask your prescriber's office to file a retroactive authorization request with supporting documentation; simultaneously file a member appeal. 4. If internal appeal fails: request independent external review. Provide the full clinical package to the external reviewer. 5. Expedited option: available at every level when standard timelines would jeopardize health.

## Documentation to Gather

• UHC's current prior-authorization criteria for this drug: download from UHC's provider portal or request from the pharmacy benefits manager. Every criterion must be addressed.
• Diagnosis confirmation: chart notes establishing the specific cardiovascular condition, its severity, and any qualifying event history.
• Step-therapy records: pharmacy printouts and chart notes documenting every prior lipid-lowering agent trialed, the duration, and the clinical outcome (inadequate response or documented intolerance).
• Current clinical status: most recent relevant lab results and a cardiologist or treating-physician summary of current risk.
• Prescriber prior-authorization letter: a signed, detailed letter addressing each criterion in UHC's published policy and in the FDA-approved prescribing label for the requested agent.

## Criteria-Mapping Structure

Obtain UHC's prior-authorization clinical criteria document for PCSK9 monoclonal antibodies. For each criterion listed, write one paragraph or bullet in your appeal that: (1) quotes the criterion exactly, (2) identifies the specific chart record or lab result that satisfies it, and (3) provides the date and source of that record. This structure prevents reviewers from finding gaps and makes approval straightforward. Attach all referenced records as exhibits, labeled to match.